Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
16.65
USD
|
+2.52%
|
|
0.00%
|
-56.18%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,243
|
1,657
|
1,073
|
1,797
|
1,787
|
-
|
-
|
Enterprise Value (EV)
1 |
1,144
|
1,597
|
1,001
|
1,797
|
1,787
|
1,787
|
1,787
|
P/E ratio
|
-11
x
|
-20.3
x
|
-6.81
x
|
-7.42
x
|
-5.82
x
|
-6.9
x
|
-6.77
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
96.5
x
|
229
x
|
490
x
|
998
x
|
-
|
896
x
|
14.7
x
|
EV / Revenue
|
96.5
x
|
229
x
|
490
x
|
998
x
|
-
|
896
x
|
14.7
x
|
EV / EBITDA
|
-18,718,797
x
|
-21,991,725
x
|
-8,390,728
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-25,204,277
x
|
-20,415,760
x
|
-9,251,959
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
11
x
|
32.5
x
|
18.5
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,712
|
37,955
|
43,551
|
47,291
|
52,402
|
-
|
-
|
Reference price
2 |
32.97
|
43.67
|
24.64
|
38.00
|
34.11
|
34.11
|
34.11
|
Announcement Date
|
3/12/21
|
2/28/22
|
3/6/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12.89
|
7.231
|
2.192
|
1.8
|
-
|
1.995
|
122
|
EBITDA
|
-66.42
|
-75.37
|
-127.9
|
-
|
-
|
-
|
-
|
EBIT
1 |
-67.44
|
-76.56
|
-129.1
|
-219.2
|
-303.9
|
-360.6
|
-296.4
|
Operating Margin
|
-523.3%
|
-1,058.83%
|
-5,890.37%
|
-12,178.94%
|
-
|
-18,074.19%
|
-243.07%
|
Earnings before Tax (EBT)
1 |
-75.63
|
-81.77
|
-145.2
|
-239.7
|
-313.6
|
-360.6
|
-296.4
|
Net income
1 |
-76.12
|
-81.77
|
-145.2
|
-241.4
|
-316
|
-360.6
|
-296.4
|
Net margin
|
-590.66%
|
-1,130.8%
|
-6,625.27%
|
-13,408.94%
|
-
|
-18,074.19%
|
-243.07%
|
EPS
2 |
-3.010
|
-2.150
|
-3.620
|
-5.120
|
-5.865
|
-4.940
|
-5.040
|
Free Cash Flow
|
-49.33
|
-81.19
|
-116
|
-
|
-
|
-
|
-
|
FCF margin
|
-382.77%
|
-1,122.76%
|
-5,291.38%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/21
|
2/28/22
|
3/6/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
99.4
|
60.8
|
71.8
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-49.3
|
-81.2
|
-116
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-128%
|
-263%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
2.990
|
1.340
|
1.330
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-1.900
|
-2.110
|
-2.870
|
-
|
-
|
-
|
-
|
Capex
|
1.36
|
0.86
|
0.69
|
-
|
-
|
-
|
-
|
Capex / Sales
|
10.58%
|
11.95%
|
31.3%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/21
|
2/28/22
|
3/6/23
|
2/28/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -56.18% | 1.79B | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +1.43% | 22.78B | | -11.04% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|